أفضل بودكاسات The Uromigos (2025)

1
Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade 40:05

2d ago40:05

40:05

Romain Banchereau joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.

1
Episode 380: The Role of SBRT in RCC 42:02

17d ago42:02

42:02

Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.

1
Episode 379: Uromigos Japan: 2024年のGU Oncologyを振り返る 31:31

20d ago31:31

31:31

3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待！

1
Episode 378: 2025 Preview of Important GU Data 41:42

23d ago41:42

41:42

Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prostate, renal and bladder cancer

1
Episode 375: Renal Cancer 2024 Highlights 43:11

1M ago43:11

43:11

David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC

1
Episode 376: Bladder Cancer 2024 Highlights 25:37

1M ago25:37

25:37

Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.

1
Episode 377: Prostate Cancer 2024 Highlights 35:12

1M ago35:12

35:12

Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss the 2024 prostate highlights from each of their unique perspectives.

1
Episode 374: Mechanisms of HIF Resistance 34:37

1M ago34:37

34:37

Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.

1
Episode 373: KEYNOTE-564 Asian OSとANNARの解説 34:05

2M ago34:05

34:05

JSCO2024で発表されたKEYNOTE-564東アジア人OSデータとANNAR biomarker studyの解説とディスカッションです

1
Episode 372: FDA Accelerated Approval Process 31:30

2M ago31:30

31:30

Dan Suzman from FDA joins us to discuss the Accelerated Approval process, requirements, successes and challenges.

1
Episode 371: TROPICS-04 Results from ESMO Asia 33:43

2M ago33:43

33:43

Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.

1
Episode 370: Artificial Intelligence in Medical Oncology 44:46

2M ago44:46

44:46

Jacob Kather joins Brian and Tom to discuss emerging AI applications in Oncology

1
Episode 369: Paper of the Month with Bishoy Faltas 45:51

2M ago45:51

45:51

Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication

1
Episode 368: Radiomics in RCC: Live from IKCS 37:00

2M ago37:00

37:00

Andrew Smith from St. Jude's joins us to discuss the emerging field of radiomics and shares his hopes and skepticism

1
Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer 56:48

3M ago56:48

56:48

Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.

1
Episode 366: ARPIs in Prostate Cancer - Are They Different? 31:51

3M ago31:51

31:51

Chris Sweeney and Rob Jones join Brian and Tom to discuss the relative merits of different ARPIs in prostate cancer.

1
Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC) 47:59

3M ago47:59

47:59

Episode 365: Silke Gillessen and Betrand Tombal join the show to discuss the APCCC meeting and recent publication.

1
Episode 364: 腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜 15:41

3M ago15:41

15:41

腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜

1
Episode 363: 前立腺がんの最新の話題〜T cell directed therapyとradioligands〜 14:23

3M ago14:23

14:23

前立腺がんの最新の話題〜T cell directed therapyとradioligands〜

1
Episode 362: 膀胱がんの最新の話題〜周術期薬物療法とADC〜 12:42

3M ago12:42

12:42

膀胱がんの最新の話題〜周術期薬物療法とADC〜

1
Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer 25:43

3M ago25:43

25:43

Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.

1
Episode 360: The SUNRISE Program in Bladder Cancer 46:19

4M ago46:19

46:19

Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.

1
Episode 359: #UromigosLive24 - IO after IO in RCC 40:41

4M ago40:41

40:41

The RCC panel at Uromigos Live 2024 discusses and debates this topic.

1
Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville 21:59

4M ago21:59

21:59

Eneste podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunoterapia enneadyuvancia de Ca urotelial músculo invasor, el uso de pembrolizumab adyuvante después de los datos del estudio AMBASSADOR y la búsqueda de biomarcadores.…

1
Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer 1:03:10

4M ago1:03:10

1:03:10

Tom leads a panel of Shilpa Gupta, Andrea Apolo, Kala Sridhar and Petros Grivas to discuss and debate this timely topic.

1
Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC 26:22

4M ago26:22

26:22

Brian moderates the panel that discusses and debates TKI, vs Ipi/Nivo vs IO/TKI

1
Episode 355: #UromigosLive24 - Radioligands in prostate cancer 54:23

4M ago54:23

54:23

The Uromigos Live 2024 panel discusses recent radioligand data including PEACE-3

1
Episode 354: #UromigosLive24 - T cell directed therapy in prostate cancer 44:00

4M ago44:00

44:00

Brian hosts a panel at Uromigos Live 2024 in Nashville with Michael Morris, Tanya Dorff and Karen Autio

1
Episode 353: #UromigosLive24 ADC session 53:28

4M ago53:28

53:28

Tom moderates a live panel of Kala Sridhar, Shilpa Gupta, Andrea Apolo and Petros Grivas on the emerging ADC data in bladder cancer

1
Episode 352: ESMO 2024 - RCC and Bladder review 26:25

4M ago26:25

26:25

Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.

1
Episode 351: ESMO 2024 review part 1: prostate cancer 18:48

4M ago18:48

18:48

Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....

1
Episode 350: ESMO 2024 - NIAGARA 23:51

5M ago23:51

23:51

Fresh of the Presidential session address, Tom discusses his data with Petros commenting.

1
Episode 349: ESMO 2024 - Uromigos Japan!! 30:56

5M ago30:56

30:56

Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.

1
Episode 348: ESMO 2024 - UpFrontPSMA 33:52

5M ago33:52

33:52

Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC

1
Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer 17:59

5M ago17:59

17:59

Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer

1
Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC 25:47

5M ago25:47

25:47

Silke Gillessen joins us to discuss her Presidential session from ESMO 2024

1
Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC 31:10

5M ago31:10

31:10

Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC

1
Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC 22:32

5M ago22:32

22:32

Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC

1
Episode 343: ESMO 2024 - TiNivo-2 Trial 31:23

5M ago31:23

31:23

Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.

1
Episode 342: ESMO 2024 Preview with Silke Gillessen 32:24

5M ago32:24

32:24

Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024

1
Episode 341: Hormone Resistance in Prostate Cancer 33:05

5M ago33:05

33:05

Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer

1
Episode 340: Cancer Immunity Cycle Update 41:50

5M ago41:50

41:50

Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.

1
Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU 18:37

6M ago18:37

18:37

María, Christina y Elena analizan los cambios recientes en las directrices de la ESMO en el cáncer de riñón, vejiga y próstata.

1
Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More 25:39

6M ago25:39

25:39

Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics

1
Episode 337: Updated NCCN Guidelines in RCC 42:38

6M ago42:38

42:38

Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC

1
Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer 35:35

6M ago35:35

35:35

Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.

1
Episode 335: Novel immune therapies for renal cancer 37:31

6M ago37:31

37:31

David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.